Group items tagged

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).

PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

Novavax has announced the execution of a contract modification to extend the base period of performance of its current contract with the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority

GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment

Scottish biotechnology firm TC BioPharm (TCB) and Japanese immuno-cell therapy company Medinet have entered into a strategic collaboration to develop a new treatment for different types of cancer.

EMA will launch a final round of targeted consultations with key stakeholders on its draft policy on proactive publication of and access to clinical-trial data at the beginning of May 2014.

Germany based drug discovery firm Evotec has entered into a research collaboration and licensing deal with Swiss biopharmaceutical firm Debiopharm Group to research and develop new cancer treatments

Dainippon Sumitomo Pharma (DSP) has received approval from Health Canada for use of Latuda (lurasidone HCl) as monotherapy or as adjunctive therapy with lithium or valproate to treat depressive episodes associated with bipolar I disorder.

PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF

GSK has received approval from FDA for its Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.

Charles River Laboratories International (CRL) has completed the previously announced acquisition of the CRO services division of Galapagos (GLPGF), which includes both Argenta and BioFocus.

US-based biotech startup DesignMedix has received a grant of $3m from the National Institutes of Health (NIH) to continue the development and manufacturing of a new anti-malarial drug.

PBR Staff Writer Published 01 May 2014 The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) Incruse Ellipta (umeclidinium) for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic.

MabVax Therapeutics and Telik sign definitive merger agreement

US-based KYTHERA Biopharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin.

A Comparison of the Cost of IVF across the World The high worth of state treatment could also be discouraging and preventive to many seeking such treatment. Worth and cash problems generally play a significant role in decision-making relating to fertility treatments. Below are the selections for cash assistance: Loans for state treatment, along with IVF - Secured and unsecured loans are procurable for coverage of state treatment (including IVF) and pharmaceutical care.

The US Food and Drug Administration (FDA) has now approved the use of Omalizumab, commercially known as Xolair, for the treatment of chronic hives

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), will be launched in the Netherlands on 13 May 2014.

Sustanon was developed by Organon Pharmaceuticals. It is an injectible oil-based blend. It is a synthetic steroid, which is derived from testosterone. It is available in both anabolic and androgenic form. Initially when it was prepared, it had only one form that is sustanon itself, but today it has many variants.

Primoteston is a popular brand of Testosterone-Enanthate manufactured by Schering and as such is of human grade quality; the highest level of quality any anabolic steroid can be. Schering is one of the oldest and most respected manufacturers of anabolic steroids and by many is considered the premier anabolic steroid pharmaceutical line.